IL10RB
Interleukin-10 receptor subunit beta
As of the edition of 20 October 2026, IL10RB (interleukin-10 receptor subunit beta, UniProt Q08334) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q08334
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Digestive system; Infections; Lungs and airways; Cancer; Hormones; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 32
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Peginterferon lambda-1a | Stopped | Phase 3 | none listed |
| Pegilodecakin | Stopped | Phase 3 | none listed |
| Eflepedocokin alfa | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 5 |
| Total on the list | 5 |